These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8014528)

  • 1. Legal bases for the control of analgesic drugs.
    Shapiro RS
    J Pain Symptom Manage; 1994 Apr; 9(3):153-9. PubMed ID: 8014528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Federal and state regulation of opioids.
    Joranson DE
    J Pain Symptom Manage; 1990 Feb; 5(1 Suppl):S12-23. PubMed ID: 1969888
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The US Opioid Crisis: Current Federal and State Legal Issues.
    Soelberg CD; Brown RE; Du Vivier D; Meyer JE; Ramachandran BK
    Anesth Analg; 2017 Nov; 125(5):1675-1681. PubMed ID: 29049113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure of enforcement controlled substance laws in health policy for prescribing opiate medications: a painful assessment of morbidity and mortality.
    Miller NS
    Am J Ther; 2006; 13(6):527-33. PubMed ID: 17122534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responsible, Safe, and Effective Prescription of Opioids for Chronic Non-Cancer Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
    Manchikanti L; Kaye AM; Knezevic NN; McAnally H; Slavin K; Trescot AM; Blank S; Pampati V; Abdi S; Grider JS; Kaye AD; Manchikanti KN; Cordner H; Gharibo CG; Harned ME; Albers SL; Atluri S; Aydin SM; Bakshi S; Barkin RL; Benyamin RM; Boswell MV; Buenaventura RM; Calodney AK; Cedeno DL; Datta S; Deer TR; Fellows B; Galan V; Grami V; Hansen H; Helm Ii S; Justiz R; Koyyalagunta D; Malla Y; Navani A; Nouri KH; Pasupuleti R; Sehgal N; Silverman SM; Simopoulos TT; Singh V; Solanki DR; Staats PS; Vallejo R; Wargo BW; Watanabe A; Hirsch JA
    Pain Physician; 2017 Feb; 20(2S):S3-S92. PubMed ID: 28226332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combating the prescription painkiller epidemic: a national prescription drug reporting program.
    Shepherd J
    Am J Law Med; 2014; 40(1):85-112. PubMed ID: 24844043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prescription drug monitoring programs in the United States of America].
    El Burai Félix S; Mack K
    Rev Panam Salud Publica; 2014 Oct; 36(4):270-6. PubMed ID: 25563153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State Legal Restrictions and Prescription-Opioid Use among Disabled Adults.
    Meara E; Horwitz JR; Powell W; McClelland L; Zhou W; O'Malley AJ; Morden NE
    N Engl J Med; 2016 Jul; 375(1):44-53. PubMed ID: 27332619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do international model drug control laws provide for drug availability?
    University of Wisconsin Pain & Policy Studies Group
    J Pain Palliat Care Pharmacother; 2009; 23(2):145-52. PubMed ID: 19492215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain.
    Fishman SM; Papazian JS; Gonzalez S; Riches PS; Gilson A
    Pain Med; 2004 Sep; 5(3):309-24. PubMed ID: 15367312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in opioid analgesic abuse and mortality in the United States.
    Dart RC; Surratt HL; Cicero TJ; Parrino MW; Severtson SG; Bucher-Bartelson B; Green JL
    N Engl J Med; 2015 Jan; 372(3):241-8. PubMed ID: 25587948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use.
    Rutkow L; Chang HY; Daubresse M; Webster DW; Stuart EA; Alexander GC
    JAMA Intern Med; 2015 Oct; 175(10):1642-9. PubMed ID: 26280092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Policy and medical-legal issues in the prescribing of controlled substances.
    Clark HW
    J Psychoactive Drugs; 1991; 23(4):321-8. PubMed ID: 1813603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State program tracks Schedule II drugs.
    Mirro MJ; Winkeljohn HA; Ragatz B
    Indiana Med; 1993; 86(2):148-51. PubMed ID: 8463644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guiding principles of international and federal laws pertaining to medical use and diversion of controlled substances.
    Joranson DE
    NIDA Res Monogr; 1993; 131():18-34. PubMed ID: 8413529
    [No Abstract]   [Full Text] [Related]  

  • 17. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement.
    Zacny J; Bigelow G; Compton P; Foley K; Iguchi M; Sannerud C
    Drug Alcohol Depend; 2003 Apr; 69(3):215-32. PubMed ID: 12633908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Balancing diversion control and medical necessity: the case of prescription drugs with abuse potential.
    Simoni-Wastila L; Tompkins C
    Subst Use Misuse; 2001; 36(9-10):1275-96. PubMed ID: 11592473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An empirical review of the impact of triplicate prescription of benzodiazepines.
    Schwartz HI
    Hosp Community Psychiatry; 1992 Apr; 43(4):382-5. PubMed ID: 1349557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of Controlled Substance Prescribing: An Overview for Certified Nurse-Midwives and Certified Midwives.
    Osborne K
    J Midwifery Womens Health; 2017 May; 62(3):341-347. PubMed ID: 28544336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.